|
 The company also raised its full-year revenue forecast range to
$8.27 billion-$8.37 billion from $8.08 billion-$8.23 billion.
The cardiac rhythm management business, which sells pacemakers and
defibrillators, had been weighing on Boston Scientific's results for
several months due to the lack of MRI-compatible products.
However, new device approvals in the business helped improve sales
in the second quarter, rising 4.5 percent from a year earlier and
18.2 percent from the first quarter to $512 million.
The company reported a net loss of $207 million, or 15 cents per
share, for the quarter ended June 30, largely due to litigation
charges. The company posted a profit of $102 million, or 8 cents per
share, a year earlier.
On an adjusted basis, Boston Scientific earned 27 cents per share,
in line with the average analyst estimate, according to Thomson
Reuters I/B/E/S.
[to top of second column] |
The company's net sales rose 15.4 percent to $2.13 billion. Analysts
on an average had expected $2.05 billion.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
